CD4 and lung cancer: As a further proof that the observed therapeutic effects are indeed mediated by the cellular immune system, the best combination therapy (namely, (R)-crizotinib plus CDDP) completely lost efficacy against TC1 lung cancers developing in athymic nu/nu mice (Fig. 4l–n, Supplementary Fig. 7b), or when CD4+ or CD8+ T lymphocytes were depleted by the injection of suitable antibodies (Supplementary Fig. 7c–e).